PPARD and metabolic dysfunction-associated steatohepatitis: After statistical reanalysis, human data supported a very modest effect of elafibranor, a combined PPARα and PPAR-β/δ agonist on the histological resolution of NASH and fibrosis with an improvement of IR and serum lipid normalization [210].